VDL-309 / Vascurie - LARVOL DELTA

AAX Biotech and Vascurie announce new neuro-oncology collaboration (PharmaTimes) - "The collaboration will use AAX’s Seqitope platform and automation infrastructure to speed up the characterisation of therapeutic antibodies. AAX will use Seqitope, which has the capacity for high-throughput epitope mapping, to characterise Vascurie’s established antibody candidates against CD93, a new neuro-oncology drug target....The company aims to submit Investigational New Drug (IND) and Clinical Trial Applications (CTA) to the US Food and Drug Administration (FDA) for VDL-309 in 2027."

IND • Licensing / partnership • CNS Tumor • High Grade Glioma